Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New inhaled drug aims to treat lung scarring with fewer side effects

NCT ID NCT06992661

Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 4 times

Summary

This early-stage trial tests a single dose of an inhaled drug called RJ026 in 42 healthy volunteers and 42 people with interstitial lung disease (ILD). The goal is to see how much drug reaches the lungs and blood, and whether it is safe. Researchers hope that inhaling the drug will deliver higher doses to the lungs while reducing side effects seen with oral versions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RJ026 inhaled powder
What this could lead to
If successful, this could lead to a more targeted treatment for interstitial lung disease with fewer side effects than oral medication.
What could go wrong
This is a very early Phase 1 trial with only 84 participants. It primarily measures safety and drug levels, not whether the drug actually improves the disease. The drug may not work or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

ICD patients: Inclusion Criteria: 1. Age ≥40 years, any gender 2. Diagnosed or suspected ILD (IPF or CTD-ILD) based on HRCT or thin-section CT 3. FVC ≥40% predicted, DLCO ≥40% predicted, FEV1/FVC ≥0.7 4. Able to tolerate bronchoscopy 5. Willing to use effective contraception during study 6. Capable of proper inhaler use Exclusion Criteria: 1. Pregnancy or lactation 2. Allergy to study drug components 3. Active respiratory infection or acute cardiopulmonary disease 4. Abnormal liver function (ALT/AST/GGT \> ULN or total bilirubin \> ULN) 5. Recent smoking (within 6 months) or alcohol abuse 6. Participation in other clinical trials within 3 months 7. Blood donation ≥400mL within 3 months 8. HBV DNA ≥2000 IU/mL or HCV RNA ≥1000 IU/mL or HIV positive

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteers Interstitial lung disease (ILD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.